Camden Hospital

South Western Sydney Local Health District

Cardiovascular Diseases

Obesity

LY3437943

Retatrutide

Lilly

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

South Western Sydney Local Health District | Camden Hospital

Site insights

Work at this site?

Active trials

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)

Trial sponsors